Durvalumab: NICE recommends new lung cancer treatment
Clinical update Previous     Next

Durvalumab: NICE recommends new lung cancer treatment

Daniel Allen Health writer

Essential facts

A new lung cancer immunotherapy treatment should be made available to some lung cancer patients in England, according to the National Institute for Health and Care Excellence (NICE).

Cancer Nursing Practice. 18, 4, 11-11. doi: 10.7748/cnp.18.4.11.s11

Want to read more?

Subscribe for unlimited access

Try 1 month’s access for just £1 and get:

Your subscription package includes:
  • Full access to the website and the online archive
  • Bi-monthly digital edition
  • RCNi Portfolio and interactive CPD quizzes
  • RCNi Learning with 200+ evidence-based modules
  • 10 articles a month from any other RCNi journal
Subscribe
RCN student member? Try Nursing Standard Student
Already subscribed? Log in

Alternatively, you can purchase access to this article for the next seven days. Buy now

Or